Oxidoreductase delivery by cell therapies in cyclophosphamide-induced premature ovarian insufficiency: a mechanistic insight into ovarian rejuvenation

The etiologically diverse decline in ovarian function among females represents a significant contributor to the rising incidence of infertility. Recent advances in cell-based therapies, including mesenchymal stem cells (MSCs) and autologous stromal vascular fraction (SVF), has shown potential in rejuvenating ovarian function. Yet, the efficacy heterogeneity and mechanisms of action warrant further investigation for validation. This study investigates the therapeutic efficacy of human umbilical cord-derived MSCs (HucMSCs), adipose tissue-derived MSCs (ADSCs), and stromal vascular fraction (SVF) in a cyclophosphamide (CTX)-induced premature ovarian insufficiency (POI) mouse model. Equivalent doses of these cells were orthotopically administered, and their impact on ovarian function was meticulously evaluated using comprehensive functional and histological assays. RNA sequencing and proteomic analysis were employed to elucidate the underlying mechanisms. Our findings reveal that HucMSCs, ADSCs, and SVF robustly enhance follicle development, hormonal balance, oocyte quality, and embryonic developmental potential, leading to improved fertility outcomes. In vitro co-culture with granulosa cells (GCs) demonstrated that all three cell types significantly promoted GC proliferation. Proteomic evaluation identified oxidoreductase enzymes as key players in mitigating ovarian injury by alleviating oxidative stress within oocytes and GCs. These results underscore the therapeutic potential of HucMSCs, ADSCs, and SVF in rejuvenating ovarian function and highlight their promise as versatile and effective cell-based therapies for clinical application in female infertility. This study provides critical insights and a foundation for advancing the clinical translation of these cell-based materials as promising agents for female infertility, offering new hope for women facing ovarian dysfunction.

Authors

Institutions

Publication Details

Journal
Journal of Ovarian Research
Published
2025-12-23
DOI
https://doi.org/10.1186/s13048-025-01912-y
Primary Topic
Reproductive Biology and Fertility
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Oxidoreductase delivery by cell therapies in cyclophosphamide-induced premature ovarian insufficiency: a mechanistic insight into ovarian rejuvenation

Dong Huang, Yingyan Chen, Xu Tong, Yingyi Zhang et al.
Journal of Ovarian Research
Reproductive Biology and Fertility
article

Oxidoreductase delivery by cell therapies in cyclophosphamide-induced premature ovarian insufficiency: a mechanistic insight into ovarian rejuvenation

Dong Huang, Yingyan Chen, Xu Tong, Yingyi Zhang, Jianmin Chen, Songying Zhang, Weijie Yang, Yan Zhou, Yin-Li Zhang, Yuqing Mei, Jiamin Jin, Yi Zhang
article en

Abstract

The etiologically diverse decline in ovarian function among females represents a significant contributor to the rising incidence of infertility. Recent advances in cell-based therapies, including mesenchymal stem cells (MSCs) and autologous stromal vascular fraction (SVF), has shown potential in rejuvenating ovarian function. Yet, the efficacy heterogeneity and mechanisms of action warrant further investigation for validation. This study investigates the therapeutic efficacy of human umbilical cord-derived MSCs (HucMSCs), adipose tissue-derived MSCs (ADSCs), and stromal vascular fraction (SVF) in a cyclophosphamide (CTX)-induced premature ovarian insufficiency (POI) mouse model. Equivalent doses of these cells were orthotopically administered, and their impact on ovarian function was meticulously evaluated using comprehensive functional and histological assays. RNA sequencing and proteomic analysis were employed to elucidate the underlying mechanisms. Our findings reveal that HucMSCs, ADSCs, and SVF robustly enhance follicle development, hormonal balance, oocyte quality, and embryonic developmental potential, leading to improved fertility outcomes. In vitro co-culture with granulosa cells (GCs) demonstrated that all three cell types significantly promoted GC proliferation. Proteomic evaluation identified oxidoreductase enzymes as key players in mitigating ovarian injury by alleviating oxidative stress within oocytes and GCs. These results underscore the therapeutic potential of HucMSCs, ADSCs, and SVF in rejuvenating ovarian function and highlight their promise as versatile and effective cell-based therapies for clinical application in female infertility. This study provides critical insights and a foundation for advancing the clinical translation of these cell-based materials as promising agents for female infertility, offering new hope for women facing ovarian dysfunction.

Journal of Ovarian ResearchVol. 19(1)
Sir Run Run Shaw Hospital (CN), Institute for Stem Cell Biology and Regenerative Medicine (IN), Soil and Fertilizer Institute of Hunan Province (CN), Zhejiang Center for Disease Control and Prevention (CN), Zhejiang University (CN)
Good health and well-being
Openalex Percentile: Top 27%
Reproductive Biology and Fertility
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.